WWTR1 and head and neck squamous cell carcinoma: In addition, considering the emerging role of YAP/TAZ in immune suppression94,95, YAP/TAZ inhibitors may be promising candidates for combination therapy with anti-PD-1 therapy against recurrent and metastatic HNSCC.